Lenalidomideas a Second-line Therapy Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory Multicentric Castleman's Disease：a Report of Two Cases and Literature Review
No standard therapy is recommended for elderly multicentric Castleman's disease (MCD) patients who failed to the first-line treatment or relapsed. Lenalidomide has been reported to be effective for relapsed/refractory MCD in foreign countries, but its effect on this disease has been rarely...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese General Practice Publishing House Co., Ltd
2022-01-01
|
| Series: | Zhongguo quanke yixue |
| Subjects: | |
| Online Access: | https://www.chinagp.net/fileup/1007-9572/PDF/1640773295382-617698484.pdf |
| _version_ | 1797217321031303168 |
|---|---|
| author | TANG Yangming, SHI Renzhou, LAN Mei, LI Xuejun, WEN Zonghua, LU Xiaochen |
| author_facet | TANG Yangming, SHI Renzhou, LAN Mei, LI Xuejun, WEN Zonghua, LU Xiaochen |
| author_sort | TANG Yangming, SHI Renzhou, LAN Mei, LI Xuejun, WEN Zonghua, LU Xiaochen |
| collection | DOAJ |
| description | No standard therapy is recommended for elderly multicentric Castleman's disease (MCD) patients who failed to the first-line treatment or relapsed. Lenalidomide has been reported to be effective for relapsed/refractory MCD in foreign countries, but its effect on this disease has been rarely reported in China. We reported two elderly patients with relapsed/refractory MCD presented with long-term remission after second-line treatment with lenalidomide, and reviewed relevant literature, then suggested that lenalidomide showed encouraging efficacy in patients with MCD, which may be an attractive alternative for relapsed/refractory MCD. Elderly patients with MCD may be more likely to benefit from lenalidomide-based treatment because of the poor general condition and various complications. |
| first_indexed | 2024-04-24T12:00:00Z |
| format | Article |
| id | doaj.art-ab50ddeed9024c51844460e906340fca |
| institution | Directory Open Access Journal |
| issn | 1007-9572 |
| language | zho |
| last_indexed | 2024-04-24T12:00:00Z |
| publishDate | 2022-01-01 |
| publisher | Chinese General Practice Publishing House Co., Ltd |
| record_format | Article |
| series | Zhongguo quanke yixue |
| spelling | doaj.art-ab50ddeed9024c51844460e906340fca2024-04-09T02:50:00ZzhoChinese General Practice Publishing House Co., LtdZhongguo quanke yixue1007-95722022-01-01250336837210.12114/j.issn.1007-9572.2021.02.061Lenalidomideas a Second-line Therapy Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory Multicentric Castleman's Disease：a Report of Two Cases and Literature ReviewTANG Yangming, SHI Renzhou, LAN Mei, LI Xuejun, WEN Zonghua, LU Xiaochen0 1.Department of Hematology，the People's Hospital of Guangxi Zhuang Autonomous Region，Nanning 530021，China 2.Department of Pathology，the People's Hospital of Guangxi Zhuang Autonomous Region，Nanning 530021，China *Corresponding author：LAN Mei，Chief physician；E-mail：2750478267@qq.com TANG Yangming and SHI Renzhou are co-first authors No standard therapy is recommended for elderly multicentric Castleman's disease (MCD) patients who failed to the first-line treatment or relapsed. Lenalidomide has been reported to be effective for relapsed/refractory MCD in foreign countries, but its effect on this disease has been rarely reported in China. We reported two elderly patients with relapsed/refractory MCD presented with long-term remission after second-line treatment with lenalidomide, and reviewed relevant literature, then suggested that lenalidomide showed encouraging efficacy in patients with MCD, which may be an attractive alternative for relapsed/refractory MCD. Elderly patients with MCD may be more likely to benefit from lenalidomide-based treatment because of the poor general condition and various complications.https://www.chinagp.net/fileup/1007-9572/PDF/1640773295382-617698484.pdf|multicentric castleman's disease|aged|lenalidomide|recurrence|refractory diseases |
| spellingShingle | TANG Yangming, SHI Renzhou, LAN Mei, LI Xuejun, WEN Zonghua, LU Xiaochen Lenalidomideas a Second-line Therapy Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory Multicentric Castleman's Disease：a Report of Two Cases and Literature Review Zhongguo quanke yixue |multicentric castleman's disease|aged|lenalidomide|recurrence|refractory diseases |
| title | Lenalidomideas a Second-line Therapy
Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory
Multicentric Castleman's Disease：a Report of Two Cases and Literature Review |
| title_full | Lenalidomideas a Second-line Therapy
Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory
Multicentric Castleman's Disease：a Report of Two Cases and Literature Review |
| title_fullStr | Lenalidomideas a Second-line Therapy
Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory
Multicentric Castleman's Disease：a Report of Two Cases and Literature Review |
| title_full_unstemmed | Lenalidomideas a Second-line Therapy
Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory
Multicentric Castleman's Disease：a Report of Two Cases and Literature Review |
| title_short | Lenalidomideas a Second-line Therapy
Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory
Multicentric Castleman's Disease：a Report of Two Cases and Literature Review |
| title_sort | lenalidomideas a second line therapy achieves long term remission in elderly patients with relapsed refractory multicentric castleman s disease a report of two cases and literature review |
| topic | |multicentric castleman's disease|aged|lenalidomide|recurrence|refractory diseases |
| url | https://www.chinagp.net/fileup/1007-9572/PDF/1640773295382-617698484.pdf |
| work_keys_str_mv | AT tangyangmingshirenzhoulanmeilixuejunwenzonghualuxiaochen lenalidomideasasecondlinetherapyachieveslongtermremissioninelderlypatientswithrelapsedrefractorymulticentriccastlemansdiseaseareportoftwocasesandliteraturereview |